DailyIQ
|
Sector:HealthcareAll sectors
Last updated 9 minutes ago

GH·Guardant Health Inc

$.
-. (-.%)
After Hours
High
$165.00
Open
$164.18
Market Cap
21.18B
52W High
$174.08
Low
$156.87
P. Close
$159.98
P/E
-
52W Low
$40.35
Fwd P/E
-336.74
DailyIQ Est.
$165.96
Technical Score (1D)
82
BUY
News Sentiment
68
BULLISH
Guardant Health will report Q2 2026 earnings on July 30 after market close, with a management webcast at 1:30 p.m. PT, so investors should prepare to assess revenue growth and potential dilution from share issuances. The company’s share price recently reached a five‑year high, underscoring strong investor sentiment around its oncology diagnostics pipeline, which suggests that the market is pricing in continued growth. Morgan Stanley upgraded Guardant to Overweight and raised its price target to $175, reflecting confidence in the pipeline and expected revenue expansion, so analysts are anticipating a positive earnings surprise. Citigroup followed suit with a Buy rating and a $215 target, reinforcing the view that precision‑medicine market expansion will support higher valuation multiples, so the next earnings report will be critical to confirm this trajectory. BofA Securities also lifted its target to $190 and maintained a Buy, citing stronger growth expectations after recent clinical milestones, so the market will be watching for any updates on FDA approvals that could validate the upside thesis. UnitedHealth’s decision to cover Guardant’s Shield colorectal cancer test for 100 million eligible members expands the test’s market penetration and is expected to boost revenue, so the earnings release will likely include guidance on the impact of this payer coverage. Analysts note that the Shield ramp’s premium remains high relative to fundamentals, creating short‑term valuation pressure, so investors should monitor any premium adjustments or guideline updates that could affect the stock’s valuation. While speculation of a strategic tie‑up with UnitedHealth has driven the stock to multi‑year highs, no formal partnership has been announced, so the next earnings call will be key to confirm or refute any potential collaboration. The inclusion of Guardant in the Russell 1000 and other major indexes has increased passive fund exposure, which could sustain momentum, so index rebalancing activity and passive inflows will be important to watch in the coming days. Finally, the insider sale by Co‑CEO AmirAli Talasaz may signal confidence or concern, so management commentary during the earnings call will help clarify the rationale behind the transaction.
Earnings Summary
Guardant Health is a precision oncology company headquartered in Palo Alto that offers blood and tissue‑based genomic profiling tests, notably the Guardant360 platform, to guide cancer treatment decisions across the care continuum. Operating within the diagnostics and research sector, Guardant focuses on liquid biopsy and advanced research tools such as GuardantINFINITY and GuardantINFORM to support both clinical and biopharmaceutical applications. In the most recent two quarters, revenue rose from $281.27 million in Q4 2025 to $301.67 million in Q1 2026, a 7.2% increase, while the prior two quarters saw a 14.2% jump from $232.09 million in Q2 2025 to $265.20 million in Q3 2025, indicating a deceleration in revenue growth momentum. EPS improved markedly, moving from a loss of $0.50 in Q4 2025 to $0.45 in Q1 2026, and from $0.44 in Q2 2025 to $0.39 in Q3 2025, with Guardant beating analyst estimates in four of the last five quarters (Q4 2024 was the only miss). Historically, the company has posted robust YoY revenue gains—39.5% from Q4 2024 to Q4 2025 and 12.6% from Q1 2025 to Q1 2026—while EPS has trended toward less negative territory, underscoring a consistent pattern of improving profitability despite operating losses. Recent news highlights UnitedHealth’s coverage of the Shield colorectal cancer test for 100 million members, a catalyst that has driven the latest revenue uptick and prompted multiple analyst upgrades to $190–$215, reflecting heightened confidence in Guardant’s pipeline and market expansion. Investors should watch for the upcoming earnings release to gauge Shield penetration, any premium adjustments, and guidance on future pipeline milestones, as these factors will be key to understanding whether the current revenue acceleration can be sustained and how it may influence Guardant’s valuation trajectory.

EPS

EstBeatMiss
$-0.84$-0.71$-0.58$-0.46$-0.33Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$-0.39 - -
Q1'26$-0.78$-0.45+42.1%
Q4'25$-0.72$-0.50+30.1%
Q3'25$-0.49$-0.39+20.3%
Q2'25$-0.51$-0.44+14.5%
Q1'25$-0.59$-0.49+17.0%

Revenue

EstBeatMiss
$185M$225M$264M$303M$342MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$324M - -
Q1'26$288M$302M+4.9%
Q4'25$279M$281M+0.9%
Q3'25 - $265M -
Q2'25 - $232M -
Q1'25 - $203M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

GH Stock Snapshot

GH is currently trading at $160.50, giving Guardant Health Inc a market cap of 21.18B. Today's range spans $156.87–$165.00, with shares opening at $164.18 and moving up $0.52 (0.3%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 68/100.

Over the past year GH has traded between $40.35 and $174.08 - the current price is +297.8% off the 52-week low and -7.8% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $152.54 (range $90.00–$200.00), implying downside of -5.0%.

The BUY technical setup for GH (82/100) is worth attention in the context of the broader Healthcare sector. At $160.50 (near 52-week highs), with 21.18B in capitalization and bullish sentiment at 68/100, this large-cap name sits at the intersection where momentum strategies and fundamental growth investors both find something to like. Annual range: $40.35–$174.08.

The combination of a BUY signal (82/100) and bullish news sentiment (68/100) puts GH on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 21.18B in Healthcare market cap without immediately moving the stock. At $160.50 (near 52-week highs in the $40.35–$174.08 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.